Kurse werden geladen...
Prognose
| Kaufen | 2 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects.» Mehr auf accessnewswire.com
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior-all achieved within six days of oral treatment.» Mehr auf accessnewswire.com
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new in vitro preclinical data generated by Eurofins supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by SKNY Pharmaceuticals, Inc. ("SKNY"). MIRA has signed a definitive agreement to acquire SKNY, and the proposed transaction remains subject to regulatory review and shareholder approval.» Mehr auf accessnewswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −1,65 Mio | 3,59% |
| EBITDA | −1,67 Mio | 1,85% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 17,79 Mio€ |
Anzahl Aktien | 17,39 Mio |
52 Wochen-Hoch/Tief | 4,27€ - 0,44€ |
| Dividenden | Nein |
Beta | 1,98 |
KGV (PE Ratio) | −2,52 |
KGWV (PEG Ratio) | 0,63 |
KBV (PB Ratio) | 15,43 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
MIRA Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase. Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung eines neuen molekularen synthetischen Tetrahydrocannabinol (THC)-Analogons, das für die Behandlung von erwachsenen Patienten mit Angstzuständen und kognitivem Verfall, der typischerweise mit Demenz im Frühstadium einhergeht, untersucht wird. Es entwickelt MIRA1a, ein synthetisches Cannabinoid-Analogon zur Behandlung von Angstzuständen und chronischen Schmerzen, indem es auf die Cannabinoid-Rezeptoren vom Typ 1 und Typ 2 abzielt. Das Unternehmen war früher unter dem Namen MIRA1a Therapeutics, Inc. bekannt. MIRA Pharmaceuticals, Inc. wurde im Jahr 2020 gegründet und hat seinen Hauptsitz in Baltimore, Maryland.
| Name | MIRA PHARMACEUTICALS INC. Aktie |
| CEO | Erez Aminov |
| Sitz | Baltimore, md USA |
| Website | |
| Industrie | Chemikalien |
| Börsengang | |
| Mitarbeiter | 2 |
Ticker Symbole
| Börse | Symbol |
|---|---|
Frankfurt | K6S.F |
Düsseldorf | K6S.DU |
München | K6S.MU |
NASDAQ | MIRA |
Assets entdecken
Shareholder von MIRA PHARMACEUTICALS INC. Aktie investieren auch in folgende Assets
